LONANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
LeonaBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$5.05−0.15 (-2.88%)
Close on Oct 19, 2026
- Market cap
- $119.82M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
81.4%
8M of 9M shares
Institutional holders
44
8 new, 3 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 10 sales
Net sold $99.42K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daniel Schneeberger | 727,481 | 7.70% | 13G (passive) | Mar 31, 2026 |
| Portman David J. | 5,502,402 | 36.90% | 13D (active) | Aug 24, 2026 |
| Steven Michael Oliveira | 1,994,649 | 5.11% | 13G (passive) | Apr 14, 2025 |
| Baselake Management, LLC | 197,481 | 5.00% | 13G (passive) | Nov 7, 2025 |
| Joseph Edelman | 1,889,403 | 19.99% | 13D (active) amendment | Aug 22, 2026 |
| Perceptive Advisors LLC | 1,859,322 | 19.99% | 13D (active) amendment | Jan 16, 2026 |
| Anders Hove | 1,492,521 | 12.10% | 13G (passive) amendment | Aug 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LONA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 1,859,322 | 19.73% | $17.09M | – | 0.26% |
| Kalehua Capital Management LLC | 787,402 | 8.36% | $7.24M | – | 2.31% |
| ADAR1 Capital Management, LLC | 777,100 | 8.25% | $7.14M | +49,619 | 0.33% |
| Acorn Capital Advisors, LLC | 634,539 | 6.73% | $5.83M | – | 1.59% |
| TCG Crossover Management, LLC | 464,398 | 4.93% | $4.27M | – | 0.10% |
| NEA Management Company, LLC | 464,398 | 4.93% | $4.27M | – | 0.27% |
| Commodore Capital LP | 464,398 | 4.93% | $4.27M | – | 0.25% |
| Spruce Street Capital LP | 393,701 | 4.18% | $3.62M | – | 0.71% |
| Blackstone Inc. | 324,638 | 3.45% | $2.98M | New | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 300,000 | 3.18% | $2.76M | New | 0.00% |
| Vanguard Capital Management LLC | 275,233 | 2.92% | $2.53M | +80,473 | 0.00% |
| Seven Fleet Capital Management LP | 154,153 | 1.64% | $1.42M | −10,523 | 0.23% |
| Propel Bio Management, LLC | 149,279 | 1.58% | $1.37M | – | 0.72% |
| Simplify Asset Management Inc. | 149,279 | 1.58% | $1.37M | – | 0.02% |
| Geode Capital Management, LLC | 80,418 | 0.85% | $739.51K | +95 | 0.00% |
| BlackRock, Inc. | 79,186 | 0.84% | $727.72K | +23,135 | 0.00% |
| Renaissance Technologies LLC | 77,424 | 0.82% | $711.53K | +13,202 | 0.00% |
| Vanguard Fiduciary Trust Co | 42,814 | 0.45% | $393.46K | +2,775 | 0.00% |
| Bank Of America Corp /De/ | 32,557 | 0.35% | $299.20K | −9 | 0.00% |
| Millennium Management LLC | 32,450 | 0.34% | $298.22K | +772 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 44 | 8M | 81.4% | 8 / 8 | 7 / 3 | 1M | 0M |
| Q1 2026 | 40 | 7M | 72.7% | 6 / 12 | 6 / 6 | 1M | 0M |
| Q4 2025 | 42 | 6M | 65.9% | 15 / 8 | 6 / 7 | 5M | 0M |
| Q3 2025 | 34 | 2M | 18.2% | 34 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LONA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 183,259 | 1.95% | $1.68M | 0.00% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 149,279 | 1.58% | $1.37M | 1.78% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 82,390 | 0.87% | $757.16K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 35,908 | 0.38% | $342.56K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 21,744 | 0.23% | $199.83K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 11,846 | 0.13% | $113.01K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 10,008 | 0.11% | $95.48K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,278 | 0.07% | $59.89K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 5,988 | 0.06% | $55.03K | 0.00% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 3,774 | 0.04% | $26.64K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 3,596 | 0.04% | $33.05K | 0.00% | Jun 30, 2026 |
| Dimensional US Core Equity 1 ETF | 2,614 | 0.03% | $18.45K | 0.00% | Jul 31, 2026 |
| U.S. Vector Equity Portfolio | 1,530 | 0.02% | $10.80K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,416 | 0.02% | $13.01K | 0.01% | Jun 30, 2026 |
| U.S. Social Core Equity 2 Portfolio | 1,253 | 0.01% | $8.85K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark James Litton | PRESIDENT and CEO, Director | 59,894 | 0.64% | Apr 13, 2026 |
| Robert Renninger | CHIEF FINANCIAL OFFICER | 15,851 | 0.17% | Apr 13, 2026 |
| Mark Worthington | GENERAL COUNSEL and CCO | 18,376 | 0.20% | Apr 13, 2026 |
| Martin Javier San | CHIEF MEDICAL OFFICER | 15,887 | 0.17% | Apr 13, 2026 |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | 25,178 | 0.27% | Apr 13, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director, 10% owner | 3,114,805 | 33.06% | Jul 10, 2026 |
| Advisors Llc Perceptive | Director, 10% owner | 329,756 | 3.50% | Jul 10, 2026 |
| Joseph Edelman | Director, 10% owner | 5,402,964 | 57.35% | Jul 10, 2026 |
| Natalie C. Holles | Director | – | – | Jun 24, 2026 |
| Grant Pickering | Director | 25,783 | 0.27% | Jun 24, 2026 |
| Michael A. Panzara | Director | 0 | – | Jun 24, 2026 |
| Kelly A. Romano | Director | 80,715 | 0.86% | Jun 24, 2026 |
| James A. Johnson | Director | 5,000 | 0.05% | Jun 24, 2026 |
| Barbara Kosacz | Director | 0 | – | Jun 24, 2026 |
| Fred Callori | Director | – | – | Jun 24, 2026 |
| Peter B. Silverman | Director | – | – | Jun 24, 2026 |
| John M. Fluke Jr | Director | 148,615 | 1.58% | Apr 13, 2026 |
| Perceptive Xontogeny Venture Fund II, LP | Director, 10% owner | – | – | Dec 23, 2025 |
| David J. Portman | 10% owner | – | – | Sep 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Renninger CHIEF FINANCIAL OFFICER | Mar 4, 2026 | Sale | −906 | $5.37 | $4.87K | 15,851 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Mar 4, 2026 | Sale | −1,359 | $5.37 | $7.30K | 25,178 |
| Mark Worthington GENERAL COUNSEL and CCO | Mar 4, 2026 | Sale | −1,328 | $5.37 | $7.13K | 18,376 |
| Martin Javier San CHIEF MEDICAL OFFICER | Mar 4, 2026 | Sale | −1,720 | $5.37 | $9.24K | 15,887 |
| Mark James Litton PRESIDENT and CEO, Director | Mar 4, 2026 | Sale | −5,156 | $5.37 | $27.69K | 57,926 |
| Robert Renninger CHIEF FINANCIAL OFFICER | Mar 3, 2026 | Option exercise | +3,900 | – | – | 16,757 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Mar 3, 2026 | Option exercise | +5,856 | – | – | 26,537 |
| Mark Worthington GENERAL COUNSEL and CCO | Mar 3, 2026 | Option exercise | +5,726 | – | – | 19,704 |
| Martin Javier San CHIEF MEDICAL OFFICER | Mar 3, 2026 | Option exercise | +7,418 | – | – | 17,607 |
| Mark James Litton PRESIDENT and CEO, Director | Mar 3, 2026 | Option exercise | +22,254 | – | – | 63,082 |
| Martin Javier San CHIEF MEDICAL OFFICER | Jan 2, 2026 | Sale | −1,644 | $6.88 | $11.31K | 10,189 |
| Mark Worthington General Counsel and CCO | Jan 2, 2026 | Sale | −876 | $6.88 | $6.03K | 13,978 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Jan 2, 2026 | Sale | −876 | $6.88 | $6.03K | 20,681 |
| Mark James Litton President and CEO, Director | Jan 2, 2026 | Sale | −2,586 | $6.88 | $17.79K | 40,828 |
| Robert Renninger Chief Financial Officer | Jan 2, 2026 | Sale | −297 | $6.88 | $2.04K | 12,857 |
| Martin Javier San CHIEF MEDICAL OFFICER | Dec 31, 2025 | Option exercise | +4,667 | – | – | 11,833 |
| Mark Worthington General Counsel and CCO | Dec 31, 2025 | Option exercise | +3,667 | – | – | 14,854 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Dec 31, 2025 | Option exercise | +3,667 | – | – | 21,557 |
| Mark James Litton President and CEO, Director | Dec 31, 2025 | Option exercise | +10,834 | – | – | 43,414 |
| Robert Renninger Chief Financial Officer | Dec 31, 2025 | Option exercise | +1,236 | – | – | 13,154 |
| Advisors Llc Perceptive Director, 10% owner | Dec 23, 2025 | Award | +329,756 | $6.35 | $2.09M | 329,756 |
| Advisors Llc Perceptive Director, 10% owner | Dec 23, 2025 | Award | +989,270 | $6.35 | $6.28M | 1,529,566 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Nov 18, 2025 | Award | +1,000 | $2.31 | $2.31K | 17,890 |
| Robert Renninger Chief Financial Officer | Nov 18, 2025 | Award | +1,000 | $2.31 | $2.31K | 11,918 |
| Martin Javier San CHIEF MEDICAL OFFICER | Jul 1, 2025 | Sale | −10,842 | $0.29 | $3.14K | 71,665 |
| Mark James Litton President and CEO, Director | Jul 1, 2025 | Sale | −25,123 | $0.29 | $7.29K | 325,802 |
| Mark Worthington General Counsel and CCO | Jul 1, 2025 | Sale | −8,526 | $0.29 | $2.47K | 111,875 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Jul 1, 2025 | Sale | −8,526 | $0.29 | $2.47K | 168,901 |
| Robert Renninger SVP, Finance and Accounting | Jul 1, 2025 | Sale | −2,897 | $0.29 | $840 | 109,186 |
| Martin Javier San CHIEF MEDICAL OFFICER | Jun 30, 2025 | Option exercise | +46,666 | – | – | 82,507 |
| Mark James Litton President and CEO, Director | Jun 30, 2025 | Option exercise | +108,334 | – | – | 350,925 |
| Mark Worthington General Counsel and CCO | Jun 30, 2025 | Option exercise | +36,666 | – | – | 120,401 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Jun 30, 2025 | Option exercise | +36,666 | – | – | 177,427 |
| Robert Renninger SVP, Finance and Accounting | Jun 30, 2025 | Option exercise | +12,359 | – | – | 112,083 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | May 19, 2025 | Award | +10,000 | $0.23 | $2.30K | 140,761 |
| Robert Renninger SVP, Finance and Accounting | May 19, 2025 | Award | +10,000 | $0.23 | $2.30K | 99,724 |
| Martin Javier San CHIEF MEDICAL OFFICER | Jan 2, 2025 | Sale | −10,826 | $0.56 | $6.06K | 35,841 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Jan 2, 2025 | Sale | −8,510 | $0.56 | $4.77K | 130,761 |
| Robert Renninger VP of Finance | Jan 2, 2025 | Sale | −2,881 | $0.56 | $1.61K | 89,724 |
| Mark James Litton President and CEO, Director | Jan 2, 2025 | Sale | −25,107 | $0.56 | $14.06K | 242,591 |
| Mark Worthington General Counsel and CCO | Jan 2, 2025 | Sale | −8,510 | $0.56 | $4.77K | 83,735 |
| Martin Javier San CHIEF MEDICAL OFFICER | Dec 31, 2024 | Option exercise | +46,667 | – | – | 46,667 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Dec 31, 2024 | Option exercise | +36,667 | – | – | 139,271 |
| Robert Renninger VP of Finance | Dec 31, 2024 | Option exercise | +12,359 | – | – | 92,605 |
| Mark James Litton President and CEO, Director | Dec 31, 2024 | Option exercise | +108,333 | – | – | 267,698 |
| Mark Worthington General Counsel and CCO | Dec 31, 2024 | Option exercise | +36,667 | – | – | 92,245 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Nov 18, 2024 | Award | +9,920 | $0.55 | $5.46K | 102,604 |
| Robert Renninger VP of Finance | Nov 18, 2024 | Award | +3,651 | $0.55 | $2.01K | 80,246 |
| Mark Worthington General Counsel and CCO | Nov 18, 2024 | Award | +3,651 | $0.55 | $2.01K | 55,578 |
| Mark Worthington GENERAL COUNSEL | Sep 5, 2024 | Sale | −2,525 | $0.57 | $1.44K | 51,927 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Sep 5, 2024 | Sale | −2,525 | $0.57 | $1.44K | 92,684 |
| Rachel Lenington COO and CDO | Sep 5, 2024 | Sale | −2,525 | $0.57 | $1.44K | 20,870 |
| Mark James Litton President and CEO, Director | Sep 5, 2024 | Sale | −5,032 | $0.57 | $2.87K | 159,365 |
| Andrew Gengos CFO and Chief Business Officer | Sep 5, 2024 | Sale | −1,272 | $0.57 | $725 | 97,532 |
| Mark Worthington GENERAL COUNSEL | Sep 3, 2024 | Award | +10,000 | – | – | 54,452 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Sep 3, 2024 | Award | +10,000 | – | – | 95,209 |
| Rachel Lenington COO and CDO | Sep 3, 2024 | Award | +10,000 | – | – | 23,395 |
| Mark James Litton President and CEO, Director | Sep 3, 2024 | Award | +20,000 | – | – | 164,397 |
| Andrew Gengos CFO and Chief Business Officer | Sep 3, 2024 | Award | +5,000 | – | – | 98,804 |
| Kelly A. Romano Director | Jun 24, 2024 | Buy | +27,400 | $2.42 | $66.31K | 80,715 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| James Litton Mark Officer, Director | Mar 4, 2026 | 5,156 | $27.66K | Mar 4, 2026 | Restricted Stock Lapse - See Remarks |
| Worthington Mark Officer | Jul 1, 2025 | 8,526 | $2.50K | Jul 1, 2025 | Restricted Stock Lapse - See Remarks |
| James Litton Mark Officer, Director | Jul 1, 2025 | 25,123 | $7.37K | Jul 1, 2025 | Restricted Stock Lapse - See Remarks |
| Church Kevin Officer | Jul 1, 2025 | 8,526 | $2.50K | Jul 1, 2025 | Restricted Stock Lapse - See Remarks |
| San Martin Javier Officer | Jul 1, 2025 | 10,842 | $3.18K | Jul 1, 2025 | Restricted Stock Lapse - See Remarks |
| Church Kevin Officer | Jan 2, 2025 | 8,510 | $4.78K | Jan 2, 2025 | Restricted Stock Lapse - See Remarks |
| San Martin Javier Officer | Jan 2, 2025 | 10,826 | $6.08K | Jan 2, 2025 | Restricted Stock Lapse - See Remarks |
| James Litton Mark Officer, Director | Jan 2, 2025 | 25,107 | $14.11K | Jan 2, 2025 | Restricted Stock Lapse - See Remarks |
| Worthington Mark Officer | Jan 2, 2025 | 8,510 | $4.78K | Jan 2, 2025 | Restricted Stock Lapse - See Remarks |
| James Litton Mark Officer, Director | Sep 5, 2024 | 5,032 | $1 | Sep 5, 2024 | Restricted Stock Lapse - See Remarks |